You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGliquidone
Accession NumberDB01251
TypeSmall Molecule
GroupsApproved
Description

Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

Structure
Thumb
Synonyms
SynonymLanguageCode
GlurenormNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
DevotanMenarini
FordiabHexpharm Jaya
GlidiabSoho
GlunormalYing Yuan
GlurenorGuidotti
GlurenormBoehringer Ingelheim
Jie ShiTianjin Institute of Pharmaceutical Research Pharmaceutical
Ka Rui LinAnjielun
LodemDexa Medica
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number33342-05-1
WeightAverage: 527.632
Monoisotopic: 527.209006493
Chemical FormulaC27H33N3O6S
InChI KeyLLJFMFZYVVLQKT-UHFFFAOYSA-N
InChI
InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
IUPAC Name
1-cyclohexyl-3-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonyl}urea
SMILES
COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,3-isoquinolinediones. These are isoquinoline derivatives carrying one C=O group at positions 1, and 3 respectively.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoquinolines and derivatives
Sub Class1,3-isoquinolinediones
Direct Parent1,3-isoquinolinediones
Alternative Parents
Substituents
  • 1,3-isoquinolinedione
  • Isoquinolone
  • Tetrahydroisoquinoline
  • Benzenesulfonamide
  • Phenethylamine
  • Anisole
  • Sulfonylurea
  • Dicarboximide
  • Cyclohexylamine
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of diabetes mellitus type 2.
PharmacodynamicsGliquidone is an anti-diabetic drug in the sulfonylurea class. In patients with diabetes mellitus, there is a deficiency or absence of a hormone manufactured by the pancreas called insulin. Insulin is the main hormone responsible for the control of sugar in the blood. Gliquidone is an antidiabetic medication which is used in those patients with adult maturity onset or non-insulin dependent diabetes (NIDDM). It works by lowering blood sugar levels by stimulating the production and release of insulin from the pancreas. It also promotes the movement of sugar from the blood into the cells in the body which need it.
Mechanism of actionThe mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeThe mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier+0.625
Caco-2 permeable-0.6185
P-glycoprotein substrateSubstrate0.7457
P-glycoprotein inhibitor IInhibitor0.6115
P-glycoprotein inhibitor IIInhibitor0.805
Renal organic cation transporterNon-inhibitor0.7921
CYP450 2C9 substrateSubstrate0.5166
CYP450 2D6 substrateNon-substrate0.8162
CYP450 3A4 substrateSubstrate0.594
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 substrateNon-inhibitor0.6454
CYP450 2D6 substrateNon-inhibitor0.9231
CYP450 2C19 substrateNon-inhibitor0.9025
CYP450 3A4 substrateInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5173
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.7477
BiodegradationNot ready biodegradable0.8693
Rat acute toxicity2.3506 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8418
hERG inhibition (predictor II)Inhibitor0.6182
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180-182U.S. Patent 3,708,486.
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0022 mg/mLALOGPS
logP3.59ALOGPS
logP4.14ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area121.88 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity139.48 m3·mol-1ChemAxon
Polarizability57.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

U.S. Patent 3,708,486.

General ReferenceNot Available
External Links
ATC CodesA10BB08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AripiprazoleHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Arsenic trioxideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
ArticaineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AsenapineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
AtazanavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Azilsartan medoxomilThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
BendroflumethiazideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
BumetanideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
BuserelinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
ChlorothiazideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
ChlorpropamideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
ChlorthalidoneThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
ClozapineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
CorticotropinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Cortisone acetateHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Cyproterone acetateHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
DabrafenibHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
DanazolHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
DarunavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
DesogestrelHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
DiazoxideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
DisopyramideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
DrospirenoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
EstropipateHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Ethacrynic acidHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Ethinyl EstradiolHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
EthynodiolHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
EtonogestrelHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
EverolimusHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
FludrocortisoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
FosamprenavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
FurosemideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
GliclazideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
GlimepirideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
GlipizideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
GlyburideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
GoserelinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
HistrelinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
HomoharringtonineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
HydrochlorothiazideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
IloperidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
IndapamideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
IndinavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
inhaled insulinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin AspartMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin DetemirMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin GlargineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin GlulisineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin LisproMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin RegularMay enhance the hypoglycemic effect of Hypoglycemic Agents.
LanreotideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
LeuprolideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LevonorgestrelHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LopinavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
LurasidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MecaserminMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Medroxyprogesterone AcetateHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Megestrol acetateHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MestranolHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MethotrimeprazineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MethyclothiazideThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
MethylprednisoloneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
MetolazoneThiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.
MifepristoneMay enhance the hypoglycemic effect of Hypoglycemic Agents.
NateglinideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
NelfinavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
NilotinibHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
NorelgestrominHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
NorethindroneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
NorgestimateHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
OctreotideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
OlanzapineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
PaliperidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
PasireotideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
PentamidineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
PiperazineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
PipotiazineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
PrednisoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
ProgesteroneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
QuetiapineHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
QuinineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
RepaglinideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
RisperidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
RitonavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
SaquinavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
SirolimusHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
SulfadiazineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
SulfamethoxazoleMay enhance the hypoglycemic effect of Hypoglycemic Agents.
SulfisoxazoleMay enhance the hypoglycemic effect of Hypoglycemic Agents.
SunitinibMay enhance the hypoglycemic effect of Hypoglycemic Agents.
TemsirolimusHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
TipranavirHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
TolazamideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
TolbutamideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
TorasemideHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
TriptorelinHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
VorinostatHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
ZiprasidoneHyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
Food InteractionsNot Available

Targets

1. ATP-binding cassette sub-family C member 8

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
ATP-binding cassette sub-family C member 8 Q09428 Details

References:

  1. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000 Oct;49(10 Suppl 2):3-6. Pubmed
  2. Harrower A: Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism. 2000 Oct;49(10 Suppl 2):7-11. Pubmed
  3. Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM: Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001 Aug;44(8):1019-25. Pubmed
  4. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. Pubmed
  5. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. Pubmed

2. ATP-sensitive inward rectifier potassium channel 8

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
ATP-sensitive inward rectifier potassium channel 8 Q15842 Details

References:

  1. Szewczyk A, Wojcik G, Lobanov NA, Nalecz MJ: The mitochondrial sulfonylurea receptor: identification and characterization. Biochem Biophys Res Commun. 1997 Jan 23;230(3):611-5. Pubmed
  2. Sato T, Costa AD, Saito T, Ogura T, Ishida H, Garlid KD, Nakaya H: Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. Epub 2005 Sep 20. Pubmed
  3. Hill RA, Rudra S, Peng B, Roane DS, Bounds JK, Zhang Y, Adloo A, Lu T: Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. Pubmed

Comments
comments powered by Disqus
Drug created on March 30, 2007 08:35 / Updated on April 25, 2014 11:50